CytomX shifts towards EpCAM
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
FDA red and green lights: December 2024
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
